Rav Emily, Sheth Rachna, Ahmad Ali H
Pediatric Oncology Fellowship Program, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Pediatrics-Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Children (Basel). 2022 Dec 9;9(12):1934. doi: 10.3390/children9121934.
Pediatric patients with cancer experience significant distress from both treatment and cancer-related pain. Careful selection of an analgesic regimen should be based upon individual patient factors, including the level of pain, response to therapy, and physiologic profile. Refractory pain is a therapeutic dilemma frequently encountered in the pediatric cancer setting. Systemic lidocaine infusions have been described as both safe and efficacious, as prior studies show patients reporting decreased pain scores and improved quality of life after lidocaine treatment. Given the favorable side effect profile of lidocaine, it has the potential to be considered for analgesia in the setting of refractory pain. This review discusses the use of systemic lidocaine infusions for analgesia in pediatric oncology patients with cancer-related pain.
患有癌症的儿科患者会因治疗和癌症相关疼痛而遭受巨大痛苦。应根据个体患者因素，包括疼痛程度、对治疗的反应和生理特征，仔细选择镇痛方案。难治性疼痛是儿科癌症治疗中经常遇到的治疗难题。全身性利多卡因输注已被描述为既安全又有效，因为先前的研究表明，患者在接受利多卡因治疗后疼痛评分降低，生活质量得到改善。鉴于利多卡因良好的副作用特征，它有可能被考虑用于难治性疼痛的镇痛治疗。本综述讨论了全身性利多卡因输注在患有癌症相关疼痛的儿科肿瘤患者中的镇痛应用。
